DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Supports pilot clinical trials for ALS that test biomarker-driven interventions or improve clinical care and symptom management, for eligible applicants that can run a clinical trial with community collaboration and a regulatory/transition plan.
⚑ Must be a clinical trial; trial must start within 12 months of award date, or 18 months for FDA-regulated studies. · Projects proposing therapeutic interventions (drug/biologic/device) must include intervention-specific biomarkers in the design. · Community collaboration is required in pre-applications and applications. · Must include a detailed Regulatory Strategy plan and a separate Transition Plan.
Unit fits — one characterization, each unit's own rules
| IPPRA | 58 good | peripheral portfolio topic: public_health; signature methods: community engaged; social/behavioral work is minor; funds evaluation research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Physical Sciences & Engineering (demo) | 35 weak | technical depth: minor; funds evaluation research (capped) |
| Tom Love Innovation Hub | 15 none | deep-tech content; no commercialization signal |
Description
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.
Applications must address one of the following focus areas:
· Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway.
· Clinical Care: Improving aspects of clinical care and symptom management for ALS.
Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies.
Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design.
All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact.
Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.
Apply
View on Grants.gov → CONTACT: Jamie Shortall Grant Officer <help@eBRAP.org>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →
Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.